Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Acute decompensated heart failure (ADHF) is a life-threatening condition characterized by the sudden worsening of heart failure symptoms, leading to fluid accumulation, breathing difficulties, and reduced cardiac output that often necessitate urgent hospitalization. As per Ronaldo Pichardo-Gonzalez et al., 2026, heart failure affects approximately 6.7 million adults aged 20 years and older in the United States, creating a substantial population at risk for ADHF. According to the acute decompensated heart failure (ADHF) pipeline analysis by Expert Market Research, key therapies include IV diuretics, vasodilators, and inotropic agents. Increasing emphasis on congestion management HF, innovative cardiovascular drugs, biomarker-guided care, and improved treatment strategies is expected to drive pipeline advancement and growth in the coming years.
-
Major companies involved in the acute decompensated heart failure (ADHF) pipeline analysis include Beacon Pharmaceuticals PLC, Implicit Bioscience, and others.
-
Leading drugs currently in the pipeline include Levosimendan, Atibuclimab (IC14), and others.
-
Advancements in inotropic agents for ADHF, expanding use of vericiguat therapy, and growing integration of ultrafiltration HF strategies are strengthening treatment approaches, supporting clinical development, improving patient outcomes, and driving pipeline expansion across acute heart failure management.
Report Coverage
The Acute Decompensated Heart Failure (ADHF) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute decompensated heart failure (ADHF) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute decompensated heart failure (ADHF). The acute decompensated heart failure (ADHF) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute decompensated heart failure (ADHF) Pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute decompensated heart failure (ADHF) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute decompensated heart failure (ADHF).
Read more about this report - Request a Free Sample
Acute Decompensated Heart Failure (ADHF) Pipeline Outlook
Acute decompensated heart failure (ADHF) is a sudden worsening of heart failure symptoms caused by the heart’s inability to pump blood effectively, leading to fluid accumulation in the lungs and peripheral tissues. It commonly occurs due to myocardial ischemia, arrhythmias, uncontrolled hypertension, infections, or poor treatment adherence. Patients often present with severe dyspnea, congestion, reduced cardiac output, and require urgent hospitalization and cardiovascular stabilization.
Acute decompensated heart failure (ADHF) treatment focuses on rapid symptom relief, hemodynamic stabilization, and prevention of organ damage. Management includes diuretics, vasodilators, inotropes, SGLT2 inhibitors heart failure therapies, sacubitril/valsartan, hemodynamic monitoring, and biomarker-guided assessment using BNP/NT-proBNP biomarker testing, particularly in severe cases requiring cardiogenic shock treatment. In February 2023, AstraZeneca announced European Union approval of dapagliflozin (Forxiga) for symptomatic heart failure across the full left ventricular ejection fraction spectrum. This advancement strengthened the role of SGLT2 inhibitors heart failure management, offering improved clinical outcomes and supporting evolving treatment strategies within the pipeline.
Acute Decompensated Heart Failure (ADHF) Epidemiology
The growing incidence and healthcare burden of the disease continue to drive interest in the ADHF drug pipeline and the development of innovative heart failure therapeutics. According to Ronaldo Pichardo-Gonzalez et al. (2026), more than 10 million emergency department encounters related to ADHF were identified in the United States, highlighting the substantial disease burden. heart failure affects approximately 6.7 million Americans and is projected to exceed 8 million cases by 2030. Rising hospital admissions, increasing treatment non-compliance, and escalating healthcare costs are accelerating demand for advanced ADHF drugs, supporting continued cardiovascular drug development and market growth.
Acute Decompensated Heart Failure (ADHF) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of acute decompensated heart failure (ADHF) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The acute decompensated heart failure (ADHF) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Cell Therapies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Acute Decompensated Heart Failure (ADHF) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total acute decompensated heart failure (ADHF) clinical trials, holds a 41% share. This is followed by phase IV with 36% share, reflecting continued clinical adoption and lifecycle expansion, and phase II with 23% share, highlighting a robust pipeline of emerging therapies that can support future market growth and innovation.
Acute Decompensated Heart Failure (ADHF) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the acute decompensated heart failure (ADHF) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, cell therapies, and peptides. The acute decompensated heart failure (ADHF) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute decompensated heart failure (ADHF). Anti-inflammatory therapies are emerging as a promising drug class in the Acute Decompensated Heart Failure (ADHF) drug pipeline, targeting the inflammatory pathways associated with disease progression. For instance, colchicine is under clinical evaluation for ADHF management. It inhibits inflammatory mediators such as interleukin-6 and C-reactive protein, helping reduce systemic inflammation and potentially improving heart failure outcomes, clinical stability, and congestion control in patients with acute decompensation.
Acute Decompensated Heart Failure (ADHF) Clinical Trials – Key Players
The EMR report for the acute decompensated heart failure (ADHF) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acute decompensated heart failure (ADHF) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acute decompensated heart failure (ADHF) clinical trials:
- Beacon Pharmaceuticals PLC
- Implicit Bioscience
- Reprieve Cardiovascular, Inc.
- Lakeland Regional Health Systems, Inc.
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Quintiles, Inc.
- Nile Therapeutics
- Windtree Therapeutics
- Trevena Inc.
Acute Decompensated Heart Failure (ADHF) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute decompensated heart failure (ADHF). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute decompensated heart failure (ADHF) drug candidates.
Drug: Levosimendan
Levosimendan, sponsored by Chittagong Medical College in collaboration with Beacon Pharmaceuticals PLC and Pi Research and Development Center, is being evaluated in a Phase 2/Phase 3 randomized, controlled, multicenter trial for patients with acute decompensated heart failure (ADHF). The study is examining the efficacy and safety of levosimendan, a calcium-sensitizing inotropic agent that enhances myocardial contractility without significantly increasing myocardial oxygen consumption. Administered as a continuous intravenous infusion, levosimendan also activates ATP-sensitive potassium channels, producing vasodilatory effects that improve cardiac output and tissue perfusion. The trial is comparing levosimendan plus standard heart failure care with standard care alone while assessing functional status, NT-proBNP levels, mortality, rehospitalization, symptom improvement, and adverse events. The study is expected to reach primary completion in October 2026, with overall completion anticipated in December 2026.
Drug: Atibuclimab (IC14)
Atibuclimab (IC14), sponsored by Implicit Bioscience, is being evaluated in a Phase 1b pilot study for the treatment of acute decompensated heart failure (ADHF). IC14 is a first-in-class monoclonal antibody targeting CD14, a key regulator of innate immune activation and inflammatory signaling. Administered as a single intravenous (IV) infusion, the drug is designed to reduce maladaptive inflammation while preserving essential immune defense mechanisms. The study is examining the safety, pharmacokinetics, pharmacodynamics, biomarker responses, and preliminary efficacy of IC14 in hospitalized ADHF patients. Researchers are also assessing its effects on heart failure severity, congestion, cardiac performance, and inflammatory markers. The estimated primary completion date is April 2026, with overall study completion expected in August 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Acute Decompensated Heart Failure (ADHF) Pipeline Insight Report
- Which companies/institutions are leading the acute decompensated heart failure (ADHF) drug development?
- Which company is leading the acute decompensated heart failure (ADHF) pipeline development activities?
- What is the current acute decompensated heart failure (ADHF) commercial assessment?
- What are the opportunities and challenges present in the acute decompensated heart failure (ADHF) pipeline landscape?
- What is the efficacy and safety profile of acute decompensated heart failure (ADHF) pipeline drugs?
- Which company is conducting major trials for acute decompensated heart failure (ADHF) drugs?
- Which companies/institutions are involved in acute decompensated heart failure (ADHF) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in acute decompensated heart failure (ADHF)?
Reasons To Buy This Report
The acute decompensated heart failure (ADHF) pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for acute decompensated heart failure (ADHF). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute decompensated heart failure (ADHF) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
